Jared Arnett
Psychiatric/Mental Health · Ste Genevieve, MONPI 1053703488
Payments from drug & device makers
Across 151 payments — averaging $19.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$496
- Alkermes, Inc.$467
- Otsuka America Pharmaceutical, Inc.$316
- Teva Pharmaceuticals USA, Inc.$312
- Johnson & Johnson$276
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$201
- plus $832 from 16 others
What the payments were for
- Food & beverage$2,78096%
- Education$1204%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 41 | $496 |
| Alkermes, Inc. | 18 | $467 |
| Otsuka America Pharmaceutical, Inc. | 17 | $316 |
| Teva Pharmaceuticals USA, Inc. | 9 | $312 |
| Johnson & Johnson | 16 | $276 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $201 |
| Lundbeck LLC | 9 | $175 |
| Neurocrine Biosciences, Inc. | 7 | $163 |
| E.r. Squibb & Sons, L.L.C. | 5 | $98 |
| Vanda Pharmaceuticals Inc. | 3 | $87 |
| Axsome Therapeutics, Inc. | 3 | $73 |
| Grifols USA, LLC | 2 | $35 |
| Acadia Pharmaceuticals Inc | 1 | $29 |
| Lilly USA, LLC | 1 | $26 |
| Baxter Healthcare | 1 | $23 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| Biogen | 1 | $21 |
| Organon | 1 | $19 |
| Philips North America LLC | 1 | $18 |
| Averitas Pharma Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Amgen | 1 | $12 |
How this compares
$2,900 in reported general payments places this provider in the 75th percentile of 565 psychiatric/mental health providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 150 | $489,795 |
| Invega TrinzaPaliperidone Palmitate | 11 | $94,120 |
| NuedextaDextromethorphan Hbr/Quinidine | 41 | $61,513 |
| RexultiBrexpiprazole | 28 | $41,270 |
| VraylarCariprazine Hcl | 16 | $29,886 |
| Clozapine | 271 | $22,183 |
| Lurasidone Hcl | 107 | $14,054 |
| TrintellixVortioxetine Hydrobromide | 47 | $13,492 |
| Olanzapine | 451 | $8,831 |
| Paliperidone ErPaliperidone | 47 | $8,191 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 79 | $6,950 |
| Fluphenazine Hcl | 18 | $5,572 |
| Duloxetine Hcl | 344 | $5,472 |
| Chlorpromazine Hcl | 65 | $5,408 |
| Quetiapine Fumarate | 289 | $4,703 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $276 | $583,915161 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $316 | $41,27028 claims |
| AbbVieVraylar | $496 | $29,88616 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $15 | $13,49247 claims |
| Lilly USA, LLCOlanzapine | $26 | $8,831451 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 565 psychiatric/mental health providers in Missouri.
Other psychiatric/mental health in Ste Genevieve
- Aldijana SacicSaint Louis$510K
- Erin DuvallSpringfield$275K
- Laurel OwensLees Summit$246K
- Julie WaterburySaint Louis$135K
- Emily WoukSpringfield$90K
- Kristerpher BrimberryPoplar Bluff$74K
- Matthew LindquistSt Louis$42K
- Stacy EmersonKennett$25K
- Jeffery DavisCreve Coeur$24K
- Kelsey KingsboroughMexico$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.